Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -6.30630630631 | 1.11 | 1.18 | 1.025 | 391227 | 1.0977661 | CS |
| 4 | -0.33 | -24.0875912409 | 1.37 | 1.4 | 1.025 | 383681 | 1.21241089 | CS |
| 12 | 0.05 | 5.05050505051 | 0.99 | 1.71 | 0.89735 | 705035 | 1.29692152 | CS |
| 26 | -0.04 | -3.7037037037 | 1.08 | 1.71 | 0.89735 | 514943 | 1.1959916 | CS |
| 52 | -0.41 | -28.275862069 | 1.45 | 1.71 | 0.88 | 614433 | 1.1638493 | CS |
| 156 | 0.29 | 38.6666666667 | 0.75 | 3.12 | 0.661 | 412156 | 1.39026181 | CS |
| 260 | -1.59 | -60.4562737643 | 2.63 | 4.96 | 0.45 | 382075 | 1.69460623 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.